We are live on ! Find out more
VBIO

Valion Bio
VBIO

8 hedge funds and large institutions have $96.3K invested in Valion Bio in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

33% more funds holding

Funds holding: 6 → 8 (+2)

14.13% less ownership

Funds ownership: 14.75% → 0.62% (-14%)

55% less capital invested

Capital invested by funds: $216K → $96.3K (-$119K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
8
Holders Change
+2
Holders Change %
+33.33%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
–
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
+$10.7K
2
CSS
Cubist Systematic Strategies
Connecticut
+$5.36K
3
Millennium Management
Millennium Management
New York
+$5.36K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$5.36K

Top Sellers

Rank Fund Capital Flow
1
WAM
Warberg Asset Management
Illinois
-$81.6K
2
UBS Group
UBS Group
Switzerland
-$10.7K
3
E
Ergoteles
New York
-$4.28K
4
Goldman Sachs
Goldman Sachs
New York
-$1.57K

VBIO Hedge Fund Activity: Q2 2023 in Review

8 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Valion Bio (VBIO) for Q2 2023, worth a combined $96.3K — down 55% from $216K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new VBIO positions and 2 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Two Sigma Securities, opening a new position worth an estimated $10.7K. The largest seller was Warberg Asset Management, exiting entirely with an estimated $81.6K sold.

  • 8 institutional investors held Valion Bio (VBIO) as of Q2 2023, up from 6 in Q1 2023.
  • Funds reported $96.3K of Valion Bio stock for Q2 2023, down 55% quarter-over-quarter.
  • 4 funds opened new Valion Bio positions in Q2 2023 and 2 closed out, a net change of +2 holders.
  • The largest Valion Bio buyer in Q2 2023 was Two Sigma Securities, an estimated $10.7K added.
  • The largest Valion Bio seller in Q2 2023 was Warberg Asset Management, an estimated $81.6K sold.

Based on aggregated 13F filings for Q2 2023.